## SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

# **SCHEDULE 13G** (Rule 13d-102)

# INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b)

Neurocrine Biosciences, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
64125C109
(CUSIP Number)
January 11, 2008
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b) ⊠ Rule 13d-1(c) o Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).

CUSIP	No. 64125C109		13G	Page 2 of 10 Pages	
1	NAME OF REF Biotechnology V	Value Fund,		ONLY):	
2			TE BOX IF A MEMBER OF A GROUP*	(a) (b) (	
3	SEC USE ONL	Y			
4	CITIZENSHIP	OR PLACE	OF ORGANIZATION		
	Delaware				
	MBER OF	5	SOLE VOTING POWER 0		
BENE	HARES EFICIALLY WNED	6	SHARED VOTING POWER <b>665,100</b>		
REI	BY EACH PORTING	7	SOLE DISPOSITIVE POWER 0		
PERSON WITH:		8	SHARED DISPOSITIVE POWER 665,100		
9	AGGREGATE PERSON	AMOUNT	BENEFICIALLY OWNED BY EACH RE	EPORTING	
	665,100				
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*				
11	PERCENT OF	CLASS RE	PRESENTED BY AMOUNT IN ROW (9	)	
	1.8%				
12	TYPE OF REF	ORTING PI	ERSON*		
	PN				

CUSIP No. 64125C109			13G Pa	ge 3 of 10 Pages	
1	NAME OF REPORTING PERSON:  Biotechnology Value Fund II, L.P.  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):				
2	CHECK THE A	APPROPRIA	TE BOX IF A MEMBER OF A GROUP*	(a) ⊠ (b) o	
3	SEC USE ONLY				
4		OR PLACE	OF ORGANIZATION		
	Delaware				
	MBER OF	5	SOLE VOTING POWER 0		
BENE	HARES EFICIALLY WNED	6	SHARED VOTING POWER 460,000		
REF	BY EACH PORTING	7	SOLE DISPOSITIVE POWER  0		
	ERSON WITH:	8	SHARED DISPOSITIVE POWER 460,000		
9					
	460,000				
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*				
11	PERCENT OF	CLASS RE	PRESENTED BY AMOUNT IN ROW (9)		
	1.2%				
12	TYPE OF REI	PORTING P	ERSON*		
	PN				

CUSIP No. 64125C109		<u> </u>	13G Page 4 of 10 Pa		
1	<b>BVF</b> Investn		PERSON: NOS. OF ABOVE PERSONS (ENTI	TIES ONLY):	
2			ATE BOX IF A MEMBER OF A GR	·	
3	SEC USE O	NLY			
4	CITIZENSH	IP OR PLACI	E OF ORGANIZATION		
	Delaware				
	BER OF	5	SOLE VOTING POWER  0		
BENEI OV	ARES FICIALLY VNED BY	6	SHARED VOTING POWER 1,606,000		
E REPO	ACH DRTING	7	SOLE DISPOSITIVE POWER 0		
PERSON WITH:		8	SHARED DISPOSITIVE POW 1,606,000	ÆR	
9	AGGREGA PERSON	ATE AMOUN	T BENEFICIALLY OWNED BY EA	ACH REPORTING	
	1,606,000				
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	4.2%				
12	TYPE OF 1	REPORTING	PERSON*		

CUSIP No. 64125C109		=	Page 5 of 1	0 Pages	
1	NAME OF REPO Investment 10, L I.R.S. IDENTIFIC	.L.C.	RSON: OS. OF ABOVE PERSONS (ENTITIES ONLY):		
2	CHECK THE AF	PPROPRIATE BOX IF A MEMBER OF A GROUP*			
3	SEC USE ONLY				
4	CITIZENSHIP O	R PLACE (	OF ORGANIZATION		
_	MBER OF	5	SOLE VOTING POWER 0		
BENE	HARES FICIALLY WNED	6	SHARED VOTING POWER 196,000		
REP	BY EACH PORTING	7	SOLE DISPOSITIVE POWER  0		
PERSON WITH:		8	SHARED DISPOSITIVE POWER 196,000		
9	AGGREGATE PERSON	TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING			
10	196,000 CHECK IF TH SHARES*	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN			
11	PERCENT OF	CLASS RE	PRESENTED BY AMOUNT IN ROW (9)		
	.5%				
12	TYPE OF REP	ORTING P	ERSON*		
	00				

CUSIP No. 64125C109		4125C109 13G Page 6 of		10 Pages	
1	NAME OF REE BVF Partners I I.R.S. IDENTIF	P.	ERSON:  OS. OF ABOVE PERSONS (ENTITIES ONLY):		
2	CHECK THE A	APPROPRIAT	TE BOX IF A MEMBER OF A GROUP*	(a) ⊠ (b) o	
3	SEC USE ONLY				
4	CITIZENSHIP	OR PLACE (	OF ORGANIZATION		
	Delaware				
	MBER OF	5	SOLE VOTING POWER 0		
BENE	HARES EFICIALLY WNED	6	SHARED VOTING POWER 2,927,100		
BY EACH REPORTING PERSON WITH:		7	SOLE DISPOSITIVE POWER  0		
		8	SHARED DISPOSITIVE POWER <b>2,927,100</b>		
9	AGGREGAT PERSON	E AMOUNT	BENEFICIALLY OWNED BY EACH REPORTING		
	2,927,100				
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	7.7%				
12	TYPE OF REPORTING PERSON* PN				

CUSIP No. 64125C109		<u> </u>	13G	Page 7 of 10 Pages	
1	NAME OF REPOBYF Inc. S.S. OR I.R.S. IDIONLY):		ERSON: TION NOS. OF ABOVE PERSONS (E	NTITIES	
2	CHECK THE AP	PROPRIA	TE BOX IF A MEMBER OF A GROU	P* (a) (b)	
3	SEC USE ONLY				
4	CITIZENSHIP O	R PLACE	OF ORGANIZATION		
	Delaware				
	BER OF	5	SOLE VOTING POWER  0		
BENEF OW	ARES FICIALLY VNED	6	SHARED VOTING POWER <b>2,927,100</b>		
E/ REPC	BY ACH DRTING	7	SOLE DISPOSITIVE POWER 0		
	RSON ITH:	8	SHARED DISPOSITIVE POWE <b>2,927,100</b>	R	
9	AGGREGAT PERSON	E AMOUI	NT BENEFICIALLY OWNED BY EAC	CH REPORTING	
	2,927,100				
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*			LUDES	
11	PERCENT C	F CLASS	REPRESENTED BY AMOUNT IN RO	OW (9)	
	7.7%				
12	TYPE OF RI	EPORTING	G PERSON*		

#### ITEM 1(a). NAME OF ISSUER:

Neurocrine Biosciences, Inc. ("NBIX")

### ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

12790 El Camino Real San Diego, California 92130

#### ITEM 2(a). NAME OF PERSON FILING:

This Schedule 13G is being filed on behalf of the following persons (the "Reporting Persons"):

- (i) Biotechnology Value Fund, L.P. ("BVF")
   (ii) Biotechnology Value Fund II, L.P. ("BVF2")
   (iii) BVF Investments, L.L.C. ("Investments")
- (iv) Investment 10, L.L.C. ("ILL10")(v) BVF Partners L.P. ("Partners")
- (vi) BVF Inc. ("BVF Inc.")

#### ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE:

The principal business office of the Reporting Persons comprising the group filing this Schedule 13G is located at 900 North Michigan Avenue, Suite 1100, Chicago, Illinois, 60611.

### ITEM 2(c). CITIZENSHIP:

BVF: a Delaware limited partnership
BVF2: a Delaware limited partnership
Investments: a Delaware limited liability company
ILL10: an Illinois limited liability company
Partners: a Delaware limited partnership
BVF Inc.: a Delaware corporation

#### ITEM 2(d). TITLE OF CLASS OF SECURITIES:

This Schedule 13G is being filed with respect to the common stock, par value \$0.001 per share ("Common Stock"), of NBIX. The Reporting Persons' percentage ownership of Common Stock is based on 37,996,885 shares of Common Stock being outstanding.

As of January 18, 2008, BVF beneficially owned 665,100 shares of Common Stock, BVF2 beneficially owned 460,000 shares of Common Stock, Investments beneficially owned 1,606,000 shares of Common Stock and ILL10 beneficially owned 196,000 shares of Common Stock. Beneficial ownership by Partners and BVF Inc. includes 2,927,100 shares of Common Stock.

CUSIP No. 64125C109 13G Page 9 of 10 Pages

#### ITEM 2(e). CUSIP Number:

64125C109

# ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS: One of the following

Not applicable as this Schedule 13G is filed pursuant to Rule 13d-1(c).

#### ITEM 4. OWNERSHIP:

The information in items 1 and 5 through 11 on the cover pages (pp. 2 - 7) on this Schedule 13G is hereby incorporated by reference.

## ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities check the following.

# ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest the funds of Ziff Asset Management, L.P., the majority member of Investments, in shares of the Common Stock beneficially owned by Investments and to vote and exercise dispositive power over those shares of the Common Stock. Partners and BVF Inc. share voting and dispositive power over shares of the Common Stock beneficially owned by BVF, BVF2, Investments and those owned by ILL10, on whose behalf Partners acts as an investment manager and, accordingly, Partners and BVF Inc. have beneficial ownership of all of the shares of the Common Stock owned by such parties.

# ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:

Not applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP:

Not applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP:

Not applicable.

### ITEM 10. CERTIFICATION

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:

January 22, 2008

#### BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert President

#### BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert President

#### **BVF INVESTMENTS, L.L.C.**

By: BVF Partners L.P., its manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert President

#### **INVESTMENT 10, L.L.C.**

By: BVF Partners L.P., its attorney-in-fact

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert President

#### **BVF PARTNERS L.P.**

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert President By: /s/ Mark N. Lampert

Mark N. Lampert President